enGene
2 known investors
enGene develops detalimogene voraplasmid (formerly EG-70), a non-viral gene therapy in clinical development to treat non-muscle invasive bladder cancer (NMIBC). The therapy is being studied in the pivotal LEGEND clinical trial.